Figure 3.
EFS by receipt of gemtuzumab in Black vs non-Black patients with CBF AML. (A) Non-Black patients. (B) Black patients.

EFS by receipt of gemtuzumab in Black vs non-Black patients with CBF AML. (A) Non-Black patients. (B) Black patients.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal